Thromb Haemost 2009; 101(05): 886-892
DOI: 10.1160/TH-08-10-0689
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism

A systematic review of management outcome studies
Marc Carrier
1   Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
2   Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
,
Marc Righini
3   Division of Angiology and Hemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Reza Karami Djurabi
4   Section of Vascular Medicine, Department of General Internal Medicine – Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
,
Menno V. Huisman
4   Section of Vascular Medicine, Department of General Internal Medicine – Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
,
Arnaud Perrier
5   Division of General Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Philip S. Wells
1   Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
2   Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
,
Marc Rodger
1   Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
2   Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
,
Walter A. Wuillemin
6   Division of Haematology and Central Haematology Laboratory Kantonsspital, Lucerne, and University of Berne Switzerland
,
Grégoire Le Gal
1   Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
7   Department of Internal Medicine and Chest Diseases, EA3878, Brest University Hospital, Brest, France
› Author Affiliations
Financial support: Marc Carrier is a recipient of a Canadian Institute for Health Research Fellowship. Philip Wells is a recipient of a Canada Research Chair. Marc Rodger is a recipient of a Career Investigator Award from the Heart and Stroke Foundation of Canada. Grégoire Le Gal is a recipient of a University of Ottawa International Fellowship.
Further Information

Publication History

Received: 23 October 2008

Accepted after major revision: 23 January 2009

Publication Date:
24 November 2017 (online)

Zoom Image

Summary

Clinical outcome studies have shown that it is safe to withhold anticoagulant therapy in patients with suspected pulmonary embolism (PE) who have a negative D-dimer result and a low pre-test probability (PTP) either using a PTP model or clinical gestalt. It was the objective of the present study to assess the safety of the combination of a negative VIDAS© D-dimer result in combination with a non-high PTP using the Wells or Geneva models to exclude PE. A systematic literature search strategy was conducted using MEDLINE, EMBASE, the Cochrane Register of Controlled Trials and all EBM Reviews. Seven studies (6 prospective management studies and 1 randomised controlled trial) reporting failure rates at three months were included in the analysis. Non-high PTP was defined as “unlikely” using the Wells’ model, or “low/intermediate” PTP using either the Geneva score, the Revised Geneva Score, or clinical gestalt. Two reviewers independently extracted data onto standardised forms. A total of 5,622 patients with low/intermediate or unlikely PTP were assessed using the VIDAS D-dimer. PE was ruled out by a negative D-dimer test in 2,248 (40%, 95% confidence intervals [CI] 38.7 to 41.3%) of them. The three-month thromboembolic risk in patients left untreated on the basis of a low/intermediate or unlikely PTP and a negative D-dimer test was 3/2,166 (0.14%, 95% CI 0.05 to 0.41%). In conclusion, the combination of a negative VIDAS D-dimer result and a non-high PTP effectively and safely excludes PE in an important proportion of outpatients with suspected PE.